MCRB241220P2000
- 0.00
- 0.000.00%
Seres Therapeutics Newsroom
Optimistic Buy Rating for Seres Therapeutics: Breakthrough Therapy Designation and Financial Stability Boost Confidence
Seres Therapeutics' SER-155 Receives FDA Breakthrough Therapy Designation for Bloodstream Infection Reduction
Express News | Seres Therapeutics Inc - FDA Meeting on Next Study of Ser-155 Expected in Q1 2025
Express News | FDA Grants Breakthrough Therapy Designation to Seres Therapeutics’ Ser-155 for Reduction of Bloodstream Infections in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplant (Allo-Hsct)
FDA Grants Breakthrough Therapy Designation to Seres Therapeutics' SER-155 for Reduction of Bloodstream Infections in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplant (Allo-HSCT)
Seres Therapeutics to Participate in Piper Sandler Healthcare Conference
Benign Growth For Seres Therapeutics, Inc. (NASDAQ:MCRB) Underpins Stock's 30% Plummet
Seres Therapeutics Price Target Maintained With a $10.00/Share by Canaccord Genuity
Seres Therapeutics Is Maintained at Buy by Canaccord Genuity
Promising Developments and Financial Stability Drive Buy Rating for Seres Therapeutics
Seres Therapeutics Reports Q3 2024 Results and Strategic Progress
Chardan Capital Maintains Buy on Seres Therapeutics, Maintains $1.25 Price Target
TD Cowen Maintains Seres Therapeutics(MCRB.US) With Buy Rating
Seres Therapeutics (MCRB) Gets a Buy From TD Cowen
Seres Therapeutics, Inc. (MCRB) Q3 2024 Earnings Call Transcript Summary
Seres Therapeutics | 10-Q: Q3 2024 Earnings Report
Seres Therapeutics, Inc. (MCRB) Q3 2024 Earnings Call Transcript
Seres Therapeutics Faces Nasdaq Challenge Amid Trial Success
Seres Therapeutics | 8-K: SERES THERAPEUTICS REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES
Seres Therapeutics GAAP EPS of -$0.33 Misses by $0.25